Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Clinical practice update: Maintain IBD remission during pandemic

Publish date:: June 10, 2020

Key clinical point: Guidelines updated for inflammatory bowel disease management during the COVID-19 pandemic.

Major finding: Selected IBD patients with COVID-19 may continue IBD management.

Study details: Expert commentary commissioned by the AGA Institute Clinical Practice Updates Committee and AGA Governing Board.

Disclosures: David T. Rubin, MD, disclosed financial relationships with AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene/Syneos, Gilead Sciences, Takeda, and many other pharmaceutical companies. Coauthors disclosed relationships with those companies and Medimmune, Novus Therapeutics, Osiris Therapeutics, RedHill Biopharma, Sanofi-Aventis, UCB Pharma, and multiple other pharmaceutical companies.

Citation:

Rubin DT et al. Gastroenterology. 2020. doi: 10.1053/j.gastro.2020.04.012.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

IBD patients prefer vedolizumab over anti-TNF drugs,

During pandemic, many gastroenterologists report low resilience, insomnia,